Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has received a consensus recommendation of “Buy” from the ...

Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the ...

Arcturus Therapeutics has a 52 week low of $12.75 and a 52 week high of $45.00. Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings data on Thursday ...

Arcturus Therapeutics Holdings Inc is a biotechnology firm based in San Diego, California, specializing in the development of innovative mRNA medicines and vaccines. With a focus on addressing ...

Learn more about whether Kymera Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

American leadership of vaccination efforts in developing countries has evaporated, along with USAid funding for the programs. New Covid-19 variants are being discovered monthly and an array of other ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

After hours: March 13 at 6:06:44 PM EDT Loading Chart for ARCT ...